KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInterest Coverage RatioInvested CapitalMarket CapitalizationNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

TherapeuticsMD (TXMD) Debt to Equity: 2011-2022

Historic Debt to Equity for TherapeuticsMD (TXMD) over the last 6 years, with Sep 2022 value amounting to -$1.94.

  • TherapeuticsMD's Debt to Equity rose 40.44% to -$1.94 in Q3 2022 from the same period last year, while for Sep 2022 it was -$11.92, marking a year-over-year increase of 19.78%. This contributed to the annual value of -$2.01 for FY2021, which is 4.91% down from last year.
  • According to the latest figures from Q3 2022, TherapeuticsMD's Debt to Equity is -$1.94, which was up 44.32% from -$3.48 recorded in Q2 2022.
  • Over the past 5 years, TherapeuticsMD's Debt to Equity peaked at $23.98 during Q2 2019, and registered a low of -$19.41 during Q1 2021.
  • Over the past 3 years, TherapeuticsMD's median Debt to Equity value was -$2.65 (recorded in 2020), while the average stood at -$4.47.
  • Within the past 5 years, the most significant YoY rise in TherapeuticsMD's Debt to Equity was 2,711.34% (2019), while the steepest drop was 1,777.30% (2019).
  • Quarterly analysis of 5 years shows TherapeuticsMD's Debt to Equity stood at $0.75 in 2018, then soared by 2,711.34% to $21.15 in 2019, then plummeted by 109.06% to -$1.92 in 2020, then declined by 4.91% to -$2.01 in 2021, then soared by 40.44% to -$1.94 in 2022.
  • Its Debt to Equity was -$1.94 in Q3 2022, compared to -$3.48 in Q2 2022 and -$1.44 in Q1 2022.